AVI BioPharma Inc., of Bothell, Wash., said it received approval from the FDA to proceed with a single oligomer, AVI-7288, in studies in both humans and nonhuman primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection. AVI-7288 is one of the two components that make up AVI-6003. AVI is conducting the work under a Department of Defense contract.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter